GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Olema Pharmaceuticals
Olema Pharmaceuticals is a biotech company focused on breast cancer treatment. Its stock price is highly volatile, driven by news about the clinical trials of its lead drug. The chart reflects investor hopes for a new approach to treating this disease.
Share prices of companies in the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for the treatment of breast cancer in women. We classify it as part of the "Breast Cancer Treatment" segment, a key area in oncology. The chart below shows the overall dynamics of this sector, where there is a high demand for new drugs.
Broad Market Index - GURU.Markets
Olema Pharmaceuticals is an oncology company developing targeted therapies for hormone-sensitive breast cancer. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Olema shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
OLMA - Daily change in the company's share price Olema Pharmaceuticals
Shares of Olema, an oncology company, exhibit high volatility, as measured by change_co. This reflects sensitivity to clinical trial results. This metric is a key component in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Breast cancer
Olema Pharmaceuticals, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with OLMA, which focuses on breast cancer treatment, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Olema is a biopharmaceutical company developing drugs to treat breast cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating Olema stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Olema Pharmaceuticals
Olema Pharmaceuticals' year-to-date performance is a classic example of an early-stage biotech company. Its 12-month market cap is entirely dependent on news of its development of a breast cancer treatment. Positive data from preclinical or early clinical trials can trigger explosive growth, while any setback can lead to a sharp decline.
Annual dynamics of market capitalization of the market segment - Breast cancer
Olema Pharmaceuticals, Inc. is a clinical-stage biotech company developing targeted therapies for the treatment of breast cancer. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this important area of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Olema Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Olema Pharmaceuticals
Olema, a biopharmaceutical company, is a speculative company. Monthly fluctuations on the chart reflect not revenue, but news about the progress of its breast cancer drug's clinical trials, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Breast cancer
This chart reflects the dynamics of the biotech sector. For Olema, an oncology company, it's the backdrop. Its volatile movements demonstrate how investor expectations surrounding the results of its targeted breast cancer drug trials are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Olema Pharmaceuticals is a clinical-stage biotech company focused on developing drugs for the treatment of breast cancer. Its value depends almost entirely on the results of clinical trials. The broader market has little impact on Olema's stock; its fate is decided in laboratories and clinics, which can lead to sharp movements counter to the market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Olema Pharmaceuticals
Olema Pharmaceuticals, a biotech company focused on breast cancer treatment, is experiencing high volatility. Its weekly stock price is a direct reaction to the publication of clinical trial data.
Weekly dynamics of market capitalization of the market segment - Breast cancer
Olema operates in the highly competitive oncology sector, where investor sentiment drives global trends. Any significant success or failure in the industry impacts everyone's risk appetite. The chart will show whether OLMA is following the general flow of biotech speculation or whether its focus on breast cancer is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Olema Pharmaceuticals, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how OLMA shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
OLMA - Market capitalization of the company Olema Pharmaceuticals
Olema Pharmaceuticals' stock price is a focused bet on a new breast cancer treatment. This biotech's market cap is entirely dependent on the success of its lead drug candidate. Its volatile dynamics reflect the market's reaction to every news item about clinical trials and regulatory decisions.
OLMA - Share of the company's market capitalization Olema Pharmaceuticals within the market segment - Breast cancer
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer. Its market capitalization reflects the potential of its lead drug. The chart below illustrates the valuation volatility typical for biotech companies during the research phase.
Market capitalization of the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. The chart below shows the market capitalization of the entire oncology sector. Olema is one of many companies searching for more effective and gentle treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. The company's market capitalization is a bet on the success of its lead drug in clinical trials. In the oncology field as a whole, its value represents the hope for new, more effective treatments for the most common cancer in women.
Book value capitalization of the company, segment and market as a whole
OLMA - Book value capitalization of the company Olema Pharmaceuticals
Olema Pharmaceuticals is built on scientific capital focused on breast cancer. The company's book value reflects its intellectual property rights to the drug OP-1250 in development and, most importantly, the funds it needs to advance it through clinical trials. The chart below shows how the company is leveraging its financial resources to achieve breakthroughs in oncology.
OLMA - Share of the company's book capitalization Olema Pharmaceuticals within the market segment - Breast cancer
Olema Pharmaceuticals, focused on breast cancer, has key tangible assets in the form of research laboratories. The S_BCap_Seg chart shows its small share of physical infrastructure, typical for a biotech company in the R&D stage.
Market segment balance sheet capitalization - Breast cancer
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Olema Pharmaceuticals, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Olema Pharmaceuticals focuses on developing drugs for breast cancer. The company's assets are not massive factories, but concentrated scientific capital and clinical trials aimed at fighting this disease. The chart shows the financial resources devoted to this important front in oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Olema Pharmaceuticals
Olema's balance sheet consists of cash in its accounts and the value of its research and development. The market, however, doesn't value these assets, but rather the potential of its drug to become a new standard in breast cancer treatment. The chart shows how much the "hope" for a breakthrough in this crucial area of oncology is worth compared to its current assets.
Market to book capitalization ratio in a market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing drugs to treat breast cancer. Its value is entirely dependent on the success of its scientific developments. This chart clearly shows how its market valuation is a bet on the future and is significantly disconnected from its current assets.
Market to book capitalization ratio for the market as a whole
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. Its valuation depends almost entirely on the success of its lead drug in clinical trials. This chart is a classic example of biotech startup valuation, with investors betting on a future breakthrough in oncology.
Debts of the company, segment and market as a whole
OLMA - Company debts Olema Pharmaceuticals
Olema Pharmaceuticals, a biotech company focused on breast cancer treatment, uses raised capital to fund its clinical trials. This chart shows how the company spends investor funds to advance its lead drug candidate through various phases of testing, a costly and risky process.
Market segment debts - Breast cancer
Olema Pharmaceuticals is a clinical-stage biotech company focused on developing targeted therapies for breast cancer. Funding expensive clinical trials is its primary goal. This chart shows how the company's debt load reflects its capital needs to advance its development through regulatory hurdles.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Olema Pharmaceuticals
Olema Pharmaceuticals is a clinical-stage biotech company focused on breast cancer treatment. Its survival and success depend on its ability to fund lengthy and expensive research. This chart shows its reliance on debt, a direct indicator of financial risk.
Market segment debt to market segment book capitalization - Breast cancer
Olema Pharmaceuticals, a clinical-stage biotech focused on developing drugs to treat breast cancer, compares its debt load to the overall market capitalization of the oncology sector. It shows how the company is funding its highly specialized but potentially breakthrough research.
Debt to book value of all companies in the market
Olema Pharmaceuticals is a clinical-stage biotech focused on breast cancer treatment. Its survival and success depend on its ability to fund long-term research. This market debt chart provides insight into overall capital availability, which is critical for companies like Olema before bringing a product to market.
P/E of the company, segment and market as a whole
P/E - Olema Pharmaceuticals
This chart for Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on breast cancer, illustrates investors' faith in its scientific approach. There is no profit. Any calculated figure reflects not current revenue, but a high estimate of the potential of its lead drug to address unmet medical needs.
P/E of the market segment - Breast cancer
Olema Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies for the treatment of breast cancer in women. Its lead drug targets a specific estrogen receptor. This chart illustrates the average valuation in the oncology development sector, where investors evaluate the scientific potential and commercial prospects of new treatments.
P/E of the market as a whole
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for the treatment of breast cancer in women. Its valuation depends on clinical trial success. This chart shows the overall market temperature. Comparison with it reveals how Olema's valuation is detached from market realities and relies solely on hopes for a scientific breakthrough in oncology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Olema Pharmaceuticals
This chart for Olema Pharmaceuticals, a biotech focused on breast cancer treatment, shows market expectations for its lead drug candidate. It reflects investor confidence in its clinical and commercial potential, which is key to assessing future profitability.
%20P%2FE%20Olema%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Olema-Pharmaceuticals&v=1772633801522 "Chart of the company's future (projected) P/E Olema Pharmaceuticals")
Future (projected) P/E of the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for the treatment of breast cancer in women. This chart shows average expectations for the biotech sector. OLMA's position may indicate the level of investor confidence in its lead drug candidate and its potential in the highly competitive oncology market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Breast-cancer&v=1772633801534 "Future (projected) P/E graph of the market segment - Breast cancer")
Future (projected) P/E of the market as a whole
Olema Pharmaceuticals is developing a targeted therapy for breast cancer. The company's valuation at this stage depends almost entirely on scientific results. Overall market sentiment, visible in this chart, influences the availability of capital but not the likelihood of clinical trial success.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772633801601 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Olema Pharmaceuticals
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. This graph visualizes the development pipeline for a new drug. Periods of loss reflect the high costs of clinical trials, while the potential sharp increase in profits is linked to the success of their lead drug candidate.
Profit of companies in the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. Profitability in this oncology segment, as the chart shows, is a high-stakes game. Years of unprofitable research can be repaid a hundredfold if a single drug is successful, helping thousands of patients and capturing a huge market.
Overall market profit
Olema Pharmaceuticals, a biopharmaceutical company focused on breast cancer treatment, is at the forefront of science. Its value and prospects are determined by the success of clinical trials and the potential of its drugs. The overall market environment, reflected in this chart, is primarily important for raising capital for further research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Olema Pharmaceuticals
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. This chart shows analyst forecasts, which are essentially bets on the success of its lead drug in clinical trials and its potential to change the standard of care.
%20profit%20of%20the%20company%20Olema%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Olema-Pharmaceuticals&v=1772633801880 "Graph of future (projected) profit of the company Olema Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer treatment in women. Its key asset is OP-1250. This chart shows the revenue forecast for the oncology sector, which for Olema reflects investor expectations for new approaches to treating one of the most common types of cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Breast-cancer&v=1772633801896 "Graph of future (predicted) profits of companies in a market segment - Breast cancer")
Future (predicted) profit of the market as a whole
Olema Pharmaceuticals is a biotech company focused on developing drugs to treat breast cancer. Its value is determined by progress in clinical trials. The overall economic outlook presented in the chart is important not for demand, but for the investment climate. During recessions, raising funding for biotech companies becomes more difficult.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772633801918 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Olema Pharmaceuticals
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. While in clinical trials, its revenue may be negligible or nonexistent. The chart reflects investor confidence in the scientific potential of its lead drug and the vast size of its addressable market, not current financial results.
P/S market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for the treatment of estrogen receptor-mediated breast cancer. The chart shows the average revenue estimate for the biotech company, providing insight into how investors value the potential of its lead drug candidate compared to the industry.
P/S of the market as a whole
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. Its valuation depends almost entirely on the success of its lead drug. The chart of average market revenue estimates serves as a reminder that investors are buying not revenue, but the hope of a breakthrough treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Olema Pharmaceuticals
Olema Pharmaceuticals is a biotech company specializing in the development of targeted therapies for breast cancer. The chart reflects investor expectations for its scientific developments, valuing the company based on the potential future revenue from its lead drug if it successfully completes clinical trials and reaches market.
%20P%2FS%20Olema%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Olema-Pharmaceuticals&v=1772633802015 "The graph of the company's future (projected) P/S Olema Pharmaceuticals")
Future (projected) P/S of the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for the treatment of breast cancer in women. This chart illustrates average future sales expectations for oncology companies. It helps investors understand how highly the market values Olema's scientific approach and the potential of its key drug candidate.
%20P%2FS%20market%20segment%20graph%20-%20Breast%20cancer&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Breast-cancer&v=1772633802069 "Future (projected) P/S market segment graph - Breast cancer")
Future (projected) P/S of the market as a whole
Olema Pharmaceuticals is a biotech company focused on breast cancer treatment. Its value is tied to the potential of one key drug. This graph of overall revenue expectations is irrelevant. Investors are focused entirely on clinical trial results, which will determine the company's future regardless of the economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772633802119 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Olema Pharmaceuticals
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. Being in the clinical stage, the company likely does not have significant sales revenue. The figures in this chart may reflect payments from partners or grants that fund its cutting-edge research.
Sales of companies in the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for the treatment of breast cancer in women. Their lead drug candidate targets a specific receptor that plays a key role in tumor development. This chart shows the sector's total revenue, reflecting the progress and commercial potential in developing new breast cancer drugs.
Overall market sales
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. This chart shows the state of the economy, but for OLMA, scientific progress is paramount. The need for new, more effective treatments for this common disease is enormous and unaffected by short-term economic fluctuations.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Olema Pharmaceuticals
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. Its future depends entirely on the success of clinical trials and approval of its drug. This chart visualizes market expectations regarding the commercial potential of its lead candidate.
%20sales%20of%20the%20company%20Olema%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Olema-Pharmaceuticals&v=1772633802315 "Schedule of future (projected) sales of the company Olema Pharmaceuticals")
Future (projected) sales of companies in the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for hormone-sensitive breast cancer. The chart shows the outlook for the oncology sector, focusing on breast cancer. Olema's future depends entirely on the success of its lead drug in clinical trials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Breast-cancer&v=1772633802347 "Schedule of future (projected) sales of companies in the market segment - Breast cancer")
Future (projected) sales of the market as a whole
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. Its long-term success depends on continued investment in research and development. This graph, illustrating overall economic confidence, influences the willingness of venture capitalists and large investors to fund multi-year clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772633802362 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Olema Pharmaceuticals
Olema Pharmaceuticals is a biotech company focused on developing new treatments for breast cancer. While in clinical trials, it incurs significant R&D expenses. This chart illustrates the company's investment in research in hopes of creating a breakthrough and highly profitable drug.
Market segment marginality - Breast cancer
Olema Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies for the treatment of breast cancer in women. This chart shows the average profitability in the oncology sector. The potential of its lead drug in a huge market allows the company to achieve profitability significantly above the industry average in the future.
Market marginality as a whole
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. The company's current financial activities are driven by investments in clinical research. This chart clearly demonstrates the gap between the costly process of developing new drugs and the current profitability of established corporations.
Employees in the company, segment and market as a whole
Number of employees in the company Olema Pharmaceuticals
Olema Pharmaceuticals is a biotech company focused on treating women's cancers. Its team consists of scientists and clinical development specialists. The growth on this chart is a positive sign, indicating that its lead drug candidate is successfully navigating the challenging phases of clinical trials.
Share of the company's employees Olema Pharmaceuticals within the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. This is a narrow but crucial area of oncology. This chart shows the percentage of leading scientists and clinicians in this specific field that Olema attracts, reflecting its scientific clout and potential to create a new standard of care for millions of women.
Number of employees in the market segment - Breast cancer
Olema Pharmaceuticals, Inc. is a biotech company focused on developing targeted therapies for breast cancer. The growth of its scientific and clinical teams, which can be seen in the chart, is a positive indicator. The accelerated hiring rate indicates that its lead drug candidate is successfully advancing through clinical trials.
Number of employees in the market as a whole
Olema Pharmaceuticals is a biotech company focused on breast cancer. Its success is determined by scientific breakthroughs, not economic cycles, as reflected in this chart. The need for new treatments is enormous and unaffected by the labor market, making its research vital in any economic environment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals is a biotech company whose market capitalization reflects investor expectations for its science. This chart is an indicator of how intellectual capital is valued. The company's entire value is attributed to its small team of scientists, resulting in a very high market capitalization per employee.
%20of%20the%20company%20Olema%20Pharmaceuticals%20(OLMA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Olema-Pharmaceuticals-OLMA&v=1772633802557 "Chart of market capitalization per employee (in thousands of dollars) of the company Olema Pharmaceuticals (OLMA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer. Its value is determined solely by the potential of its scientific developments, not the size of its team. This chart illustrates how investors value the company's intellectual capital per scientist.
%20by%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Breast-cancer&v=1772633802581 "Market capitalization per employee (in thousands of dollars) by market segment - Breast cancer")
Market capitalization per employee (in thousands of dollars) for the overall market
Olema Pharmaceuticals is a clinical-stage biotech company focused on breast cancer treatment. The chart illustrates the market valuation of its scientific potential. The very high market capitalization per employee indicates that investors are investing in the potential breakthrough that a small team of scientists can achieve.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772633802603 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals is a biotech company specializing in breast cancer treatment. They are developing targeted therapies. Like most clinical-stage biotechs, this graph likely shows a negative value. It measures the investment (loss) per scientist working on the development of the next generation of drugs.
%20Chart%20Olema%20Pharmaceuticals%20(OLMA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Olema-Pharmaceuticals-OLMA&v=1772633802634 "Company Profit Per Employee (in thousands of dollars) Chart Olema Pharmaceuticals (OLMA)")
Profit per employee (in thousands of dollars) in the market segment - Breast cancer
Olema (OLMA) is a biotech R&D company (breast cancer). This chart shows the benchmark for "Breast Cancer Treatment" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Breast-cancer&v=1772633802671 "Chart of profit per employee (in thousands of dollars) in the market segment - Breast cancer")
Profit per employee (in thousands of dollars) for the market as a whole
Olema Pharmaceuticals (OLMA) is a clinical-stage biotech focused on breast cancer treatment. The company is developing new drugs but is not yet commercially profitable. This chart shows the R&D investment (loss) per scientist, which is typical for a biotech company searching for breakthrough therapies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772633802680 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals is a biotech company focused on breast cancer treatment. For a research-stage company, this graph reflects key successes in monetizing research, such as receiving advance payments from major pharmaceutical partners for licensing promising developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Olema-Pharmaceuticals-OLMA&v=1772633802728 "Sales chart per company employee Olema Pharmaceuticals (OLMA)")
Sales per employee in the market segment - Breast cancer
Olema (OLMA) is a clinical-stage biotech company specializing in breast cancer treatment. The company has no approved products or commercial revenue. This graph doesn't reflect their value. Like other R&D biotechs, staff productivity on this graph would be zero. The company is relying entirely on the success of clinical trials.
Sales per employee for the market as a whole
Olema Pharmaceuticals is a biotech company specializing in breast cancer. This metric is expectedly low at the clinical development stage. The company is investing in its research staff without a commercial product. This schedule is important for tracking the future transition to commercialization and assessing the potential operating leverage of their developments.
Short shares by company, segment and market as a whole
Shares shorted by company Olema Pharmaceuticals (OLMA)
Olema (OLMA) is a biotech company focused on breast cancer. They are developing a new type of therapy (CERAN) that targets the estrogen receptor, which fuels many tumors. This chart shows bearish bets. Skeptics doubt their approach will be more effective than existing treatments or the success of their clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Olema-Pharmaceuticals-OLMA&v=1772633802828 "Short Shares Chart for the Company Olema Pharmaceuticals (OLMA)")
Shares shorted by market segment - Breast cancer
Olema Pharmaceuticals (OLMA) is a clinical-stage biotech developing a targeted therapy (CERAN) for the treatment of hormone-resistant breast cancer. This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting a sector, they don't believe risky R&D will succeed. For Olema, this signals a "venture drought" for funding trials.
Shares shorted by the overall market
Olema Pharmaceuticals (OLMA) is a clinical-stage biotech company specializing in breast cancer treatment. This chart measures overall market pessimism. When investors are fearful (the indicator rises), they flee en masse from speculative biotechs that lack profitability. OLMA shares may be falling simply due to risk-off sentiment, not because of problems in their development pipeline.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or a general aversion to risk in biotech, indicating potential pessimism.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Olema-Pharmaceuticals-OLMA&v=1772633802949 "RSI 14 indicator chart for the company's stock Olema Pharmaceuticals (OLMA)")
RSI 14 Market Segment - Breast cancer
Olema Pharmaceuticals is a biopharmaceutical company focused on breast cancer treatment. Its lead candidate is an oral drug (OP-1250) that targets the estrogen receptor. This chart shows the overall sentiment in the breast cancer biotech sector. It helps separate OLMA's performance from the general "noise" in the biotech sector.
RSI 14 for the overall market
Olema Pharmaceuticals (OLMA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OLMA (Olema Pharmaceuticals)
Olema Pharmaceuticals is a biotech company focused on developing targeted therapies for breast cancer, specifically an oral drug (OP-1250). This chart shows the average target price. Analysts' estimates are based on clinical data, the competitive landscape, and the drug's market potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OLMA-Olema-Pharmaceuticals&v=1772633803010 "A chart showing analyst consensus forecasts for the expected stock price. OLMA (Olema Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price OLMA (Olema Pharmaceuticals)
Olema Pharmaceuticals is a clinical-stage biotech focused *only* on breast cancer. They are developing a new generation of targeted therapies for breast cancer resistant to existing therapies. This chart reflects analysts' speculative expectations for their lead drug candidate.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OLMA-Olema-Pharmaceuticals&v=1772633803055 "A chart showing the difference between the consensus forecast and the actual stock price. OLMA (Olema Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Breast cancer
Olema Pharmaceuticals is a biotech company focused on breast cancer treatment. It is developing new oral drugs (tablets) targeting the estrogen receptor. This chart shows general expectations for the breast cancer sector, reflecting whether experts believe in new R&D approaches in this field.
Analysts' consensus forecast for the overall market share price
Olema Pharmaceuticals is a clinical-stage biotech company focused on developing drugs for the treatment of hormone-resistant breast cancer. This chart shows the overall risk appetite. For Olema, as a highly focused biotech, overall market optimism is crucial for raising the capital needed to conduct expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Olema Pharmaceuticals
Olema Pharmaceuticals is a clinical-stage biotech focused on developing targeted therapies for breast cancer. Their lead drug targets the estrogen receptor (ER). This graph is a pure reflection of their science. Its performance is entirely dependent on their clinical trial progress and market confidence in their R&D pipeline.
AKIMA Market Segment Index - Breast cancer
Olema (OLMA) is a clinical-stage biotech focused on breast cancer; the company is developing a novel oral (tablet) drug (Palazestrant) for the treatment of ER+ breast cancer. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (breast cancer) R&D focus (OLMA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Olema Oncology is a biotech company developing targeted treatments for women's cancers (breast cancer). This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this scientific story.
